Invivyd Inc. (IVVD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.75 (+0.90%), Market cap $0.36B, 52-week low–high $0.52 ~ $2.88.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncyt
Financial statements, price targets, institutional (13F) holdings and related news for Invivyd Inc. are updated in real time on BlackAll Trade.
Invivyd Inc. trades at $0.75 (+0.90%). Real-time quotes and charts are available on BlackAll Trade.
Invivyd Inc. has a market cap of about $0.36B.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in